Catharina Hagerling
Lund University
CancerInnate immune systemCytotoxic T cellTumor necrosis factor alphaImmunologyCD163Metastatic breast cancerTumor microenvironmentTumor initiationMetastasisTumor progressionFOXP3Primary tumorLymph nodeMonocyteCancer researchBreast cancerMedicineBiomarker (medicine)Estrogen receptorBiologyImmune systemCancer cell
19Publications
8H-index
693Citations
Publications 17
Newest
#1Balazs AcsH-Index: 12
#2Irma Fredriksson (KI: Karolinska Institutet)H-Index: 13
Last. Johan HartmanH-Index: 30
view all 9 authors...
We compared estrogen receptor (ER), progesterone receptor (PR), human epidermal growth-factor receptor 2 (HER2), Ki67, and grade scores among the pathology departments in Sweden. We investigated how ER and HER2 positivity rates affect the distribution of endocrine and HER2-targeted treatments among oncology departments. All breast cancer patients diagnosed between 2013 and 2018 in Sweden were identified in the National Quality Register for Breast Cancer. Cases with data on ER, PR, HER2, Ki67, gr...
Source
#1Jenny Stenström (Lund University)
#2Ingrid Hedenfalk (Lund University)H-Index: 26
Last. Catharina Hagerling (Lund University)H-Index: 8
view all 3 authors...
BACKGROUND Patients diagnosed with metastatic breast cancer have poor outcome with a median survival of approximately 2 years. While novel therapeutic options are urgently needed, the great majority of breast cancer research has focused on the primary tumor and less is known about metastatic breast cancer and the prognostic impact of the metastatic tumor microenvironment. Here we investigate the immune landscape in unique clinical material. We explore how the immune landscape changes with metast...
Source
#1Mette Hambraeus (Lund University)H-Index: 5
#2Jenny Karlsson (Lund University)H-Index: 22
Last. David Gisselsson (Lund University)H-Index: 49
view all 6 authors...
This study aims to characterize the molecular signatures of sacrococcygeal teratomas (SCTs). Methods: Three SCTs were analyzed with whole genome genotyping. RNA sequencing of 10 SCTs dominated by m...
Source
#1Aamna J. AbbasiH-Index: 1
view all 23 authors...
Source
#1Catharina Hagerling (UCSF: University of California, San Francisco)H-Index: 8
#2Mark Owyong (UCSF: University of California, San Francisco)H-Index: 5
Last. Vicki Plaks (UCSF: University of California, San Francisco)H-Index: 20
view all 14 authors...
Novel biomarkers are required to discern between breast tumors that should be targeted for treatment from those that would never become clinically apparent and/or life threatening for patients. Moreover, therapeutics that specifically target breast cancer (BC) cells with tumor-initiating capacity to prevent recurrence are an unmet need. We investigated the clinical importance of LGR5 in BC and ductal carcinoma in situ (DCIS) to explore LGR5 as a biomarker and a therapeutic target. We stained BC ...
1 CitationsSource
#1Frida Björk Gunnarsdottir (Lund University)H-Index: 1
#2Catharina Hagerling (Lund University)H-Index: 8
Last. Karin Leandersson (Lund University)H-Index: 24
view all 12 authors...
Abstract Patients with estrogen receptor α positive (ERα+) breast cancer can respond to endocrine therapy, but treatment resistance is common and associated with downregulation of ERα expression in the dormant residual cells. Here we show, using long-term NSG xenograft models of human breast cancer and primary human monocytes, in vitro primary cell cultures and tumors from breast cancer patients, that macrophage derived tumor necrosis factor alpha (TNFα) downregulates ERα in breast cancer cells ...
3 CitationsSource
#1Frida Björk Gunnarsdottir (Lund University)H-Index: 1
#2Catharina Hagerling (Lund University)H-Index: 8
Last. Karin Leandersson (Lund University)H-Index: 24
view all 10 authors...
Breast cancers are divided into different subtypes based on receptor expression status: estrogen receptor (ER), progesterone receptor (PR) and Her2. The luminal A subtype (ER+PR+Her2-) is most often associated with a good prognosis while the triple-negative (TN) cancers (ER-PR-Her2-) have a poor prognosis. ER+ cancer cells depend on estrogen for their growth and can be treated with drugs to block its effects. While most human breast cancers express ER alpha, some tumors are hormone independent d...
Source
#1Karolina I. Smolag (Lund University)H-Index: 2
#2Christine M. Mueni (Lund University)H-Index: 1
Last. Anna M. Blom (Lund University)H-Index: 75
view all 9 authors...
ABSTRACTMacrophages are a major immune cell type in the tumor microenvironment, where they display a tumor-supporting phenotype. Factor H (FH) is a complement inhibitor that also plays a role in se...
2 CitationsSource
#1Catharina Hagerling (UCSF: University of California, San Francisco)H-Index: 8
#2Hugo Gonzalez (UCSF: University of California, San Francisco)H-Index: 4
Last. Zena Werb (UCSF: University of California, San Francisco)H-Index: 179
view all 10 authors...
Metastatic behavior varies significantly among breast cancers. Mechanisms explaining why the majority of breast cancer patients never develop metastatic outgrowth are largely lacking but could underlie the development of novel immunotherapeutic target molecules. Here we show interplay between nonmetastatic primary breast cancer and innate immune response, acting together to control metastatic progression. The primary tumor systemically recruits IFNγ-producing immune effector monocytes to the lun...
21 CitationsSource
#1Hugo Gonzalez (UCSF: University of California, San Francisco)H-Index: 4
#2Catharina Hagerling (UCSF: University of California, San Francisco)H-Index: 8
Last. Zena Werb (UCSF: University of California, San Francisco)H-Index: 179
view all 3 authors...
Author(s): Gonzalez, Hugo; Hagerling, Catharina; Werb, Zena | Abstract: The presence of inflammatory immune cells in human tumors raises a fundamental question in oncology: How do cancer cells avoid the destruction by immune attack? In principle, tumor development can be controlled by cytotoxic innate and adaptive immune cells; however, as the tumor develops from neoplastic tissue to clinically detectable tumors, cancer cells evolve different mechanisms that mimic peripheral immune tolerance in ...
334 CitationsSource